daclizumab (Zinbryta)
Jump to navigation
Jump to search
Introduction
Withdrawn from worldwide market March 2018 due to reports of meningoencephalitis in Europe[5]
Indications
Adverse effects
- hepatotoxicity, increased serum ALT
- hypersensitivity reactions (anaphylaxis or angioedema)
- increased risk of infections
- symptoms of depression &/or suicidal ideation
- most common
- pharyngitis, nasopharyngitis, upper respiratory tract infection
- rash, dermatitis, eczema
- influenza,
- lymphdenopathy
- increased serum ALT
- depression
- meningoencephalitis[5]
- drug adverse effects of immunosuppressive agents
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
More general terms
References
- ↑ Journal Watch 20(17):133, 2000
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
- ↑ 3.0 3.1 Deprecated Reference
- ↑ 4.0 4.1 FDA News Release. May 27, 2016 FDA approves Zinbryta to treat multiple sclerosis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm
- ↑ 5.0 5.1 5.2 George J MS Drug Daclizumab Pulled from Worldwide Market Inflammatory encephalitis, meningoencephalitis reported in Europe . MedPage Today, March 2, 2018 https://www.medpagetoday.com/neurology/multiplesclerosis/71501
FDA Drug Safety & Availability. March 14, 2018 FDA working with manufacturers to withdraw Zinbryta from the market in the United States. https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm